Progressive Numbness, Burning Pain, Imbalance, and Dryness

2021 ◽  
pp. 125-127
Author(s):  
Shahar Shelly ◽  
Divyanshu Dubey

A 65-year-old woman was evaluated for progressive numbness and tingling involving different body parts. Onset was with her right foot. Numbness and paresthesia progressed to her left hand and then left foot. Numbness and tingling of her right hand also developed. Progressive gait instability also developed, leading to frequent falls. She started using a cane to walk. She also reported severe dry eyes and mouth and noticed an inability to sweat in hot weather. Her neurologic examination showed pseudoathetosis with eye closure and sensory gait ataxia. She had profound vibration and proprioceptive loss in all extremities (lower extremities greater than upper extremities). She also had asymmetric reduction in pinprick sensation in her hands and feet distally. She had minimal distal weakness involving her toes and upper extremities. Her deep tendon reflexes were reduced in the upper limbs and absent in the lower limbs. Toes were downgoing to plantar stimulation. Nerve conduction studies demonstrated asymmetric, sensory-predominant, axonal peripheral neuropathy with absent left median and ulnar sensory responses and relatively preserved (reduced) right median and ulnar sensory responses. Bilateral sural sensory responses were absent. Motor responses were relatively preserved. Cerebrospinal fluid analysis showed mildly increased protein concentration, and 5 cerebrospinal fluid-restricted oligoclonal bands. Thermoregulatory sweat testing showed anhidrosis involving the proximal limbs and the trunk and hypohidrosis of the forehead and distal extremities. Serum laboratory investigations identified an increased erythrocyte sedimentation rate. Serologic testing was remarkable for positive antinuclear antibody, rheumatoid factor, and Sjögren syndrome-A antibody. Chest computed tomography showed a nonspecific solitary nodule in the right upper lobe but was otherwise normal. The patient was diagnosed with Sjögren sensory ganglionopathy (or neuronopathy). The patient received a 12-week course of intravenous methylprednisolone. She was also started on mycophenolate mofetil. Two weeks later, the mycophenolate mofetil dose was increased. At follow-up 4 months later, she reported improvement in neuropathic pain, but the sensory loss and ataxia continued to be treatment refractory. The presence of sicca symptoms (dry eyes and mouth), polyarthralgias, morning stiffness, and anti-Ro antibody seropositivity were supportive of a Sjögren syndrome diagnosis. Sjögren syndrome has been associated with various neuropathic presentations. Sensory ganglionopathy in Sjögren syndrome usually presents with asymmetrical sensory loss, neuropathic pain, sensory ataxia, and sometimes pseudoathetosis, which were presenting features in this case patient.

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 71
Author(s):  
Yong-Soo Byun ◽  
Hyun Jung Lee ◽  
Soojung Shin ◽  
Moon Young Choi ◽  
Hyung-Seung Kim ◽  
...  

Autophagy has been suggested to have an important role in the pathogenesis of Sjögren syndrome (SS). We previously identified that autophagy related 5 (ATG5) was elevated in the tear and conjunctival epithelial cells of SS dry eyes (DE) compared to non-SS DE. The purpose of this study was to investigate the role of tear ATG5 as a potential biomarker in the diagnosis of SS. To confirm this hypothesis, we evaluated the tear ATG5 concentration, and other ocular tests (Schirmer I, tear breakup time (TBUT), ocular surface staining (OSS) score, ocular surface disease index (OSDI)) in SS and non-DE, and compared their diagnostic performance to discriminate SS from non-SS DE. Tear ATG5 showed the greatest area under the curve (AUC = 0.984; 95% CI, 0.930 to 0.999) among the tests, and a 94.6% sensitivity and 93.6% specificity at a cutoff value of >4.0 ng/mL/μg. Our data demonstrated that tear ATG5 may be helpful as an ocular biomarker to diagnose and assess SS. In the future, the diagnostic power of tear ATG for SS should be validated.


2011 ◽  
Vol 15 (1) ◽  
pp. 8-14 ◽  
Author(s):  
Ashley Kittridge ◽  
Shannon B. Routhouska ◽  
Neil J. Korman

Background: Sjögren syndrome (SS) is a chronic autoimmune inflammatory disease that involves primarily the exocrine glands, resulting in their functional impairment. SS typically presents as dry eyes (xerophthalmia) and dry mouth (xerostomia). This process can manifest either as the independent phenomenon of primary SS or as secondary SS when found in the context of another autoimmune process, most commonly rheumatoid arthritis or systemic lupus erythematosus. Nearly half of the patients with SS develop cutaneous manifestations, which may include dry skin (xeroderma), palpable and nonpalpable purpura, and/or urticaria-like lesions. These cutaneous manifestations have been underemphasized because they are often overshadowed by the more prominent sicca symptoms. However, certain skin findings are of paramount clinical and prognostic importance as they confer an increased risk for the development of life-threatening conditions, including multisystem vasculitis and non-Hodgkin lymphoma. Objective and Conclusions: In this review, the cutaneous manifestations of primary SS are discussed, with an emphasis on those findings that portend an increased risk of mortality. Antécédent: Le syndrome de Sjögren (SS) est une maladie autoimmune inflammatoire chronique qui affecte principalement les glandes exocrines, menant à leur incapacité fonctionnelle. SS se caractérise typiquement par une xérophtalmie (sècheresse des yeux) et une xérostomie (bouche sèche). Ces symptômes peuvent apparaître en tant que manifestations indépendantes du SS primaire ou comme SS secondaire, c'est-à-dire comme conséquence d'une autre affection autoimmune, le plus souvent l'arthrite rhumatoïde, ou le lupus érythémateux systémique. Près de la moitié des patients présente des manifestations cutanées de la maladie, dont une peau sèche (xérodermie) et des lésions palpables ou non de purpura ou ressemblant à l'urticaire. Ces manifestations cutanées n'ont pas été suffisamment soulignées car elles sont souvent éclipsées par des symptômes plus notables de la maladie. Toutefois, certaines manifestations cutanées sont d'une grande importance dans le diagnostic clinique et dans le pronostic, car elles représentent une indication d'un risque plus élevé de développer une maladie mortelle telle que la vascularite multisystémique et le lymphome non hodgkinien.


2011 ◽  
Vol 22 ◽  
pp. S36
Author(s):  
Sónia Gonçalves ◽  
Tiago Pereira ◽  
Sara Estrela ◽  
Ana Rita Cardoso ◽  
Cristina Gonçalves ◽  
...  

Medicine ◽  
2016 ◽  
Vol 95 (13) ◽  
pp. e3132 ◽  
Author(s):  
Camille Louvet ◽  
Salwan Maqdasy ◽  
Marielle Tekath ◽  
Vincent Grobost ◽  
Virginie Rieu ◽  
...  

2008 ◽  
Vol 23 (2) ◽  
pp. 32-34
Author(s):  
Laurence Ian Tan ◽  
José Florencio F. Lapeña

Objective: To describe a case of Sicca syndrome, review the literature on and discuss the diagnostic criteria for Sjögren Syndrome. Methods: Design: Case report Setting: Private Clinic  Patients: One Results: A 41-year-old female presenting with throat dryness, dry eyes, bilateral parotid enlargement, vaginal dryness and multiple joint pains previously seen by four specialists over three decades was finally diagnosed with Sjögren syndrome. Conclusion:  Sjögren syndrome presents uncommonly. As the presentation and clinical course should be taken as a whole, and no single test can be considered as a gold standard for its diagnosis, the disease entity may actually be under diagnosed, misdiagnosed or frequently present as diagnostic dilemmas. A comprehensive history and physical examination beyond the usual focus of the otorhinolaryngologic evaluation is the key for the astute clinician. Our experience may indicate a need for further evaluation of the EU revised criteria for Sjögren syndrome classification in the local setting.   Keywords: sicca syndrome, sjogren syndrome, keratoconjunctivitis sicca, stomatitis sicca, xerostomia, dysparenuia  


2016 ◽  
Vol 18 (2) ◽  
pp. 104-106
Author(s):  
Bhavesh Trikamji ◽  
Nastaran Rafiei ◽  
Hadi Mohammadkhanli ◽  
Shri K. Mishra

2017 ◽  
Author(s):  
Stephanie L Giattino ◽  
E William St. Clair

Primary Sjögren syndrome (SS) is a chronic inflammatory disease affecting the lacrimal and salivary glands, resulting in dry eyes and dry mouth. It may also lead to systemic manifestations, including fatigue, arthritis, lung involvement, kidney disease, neuropathy, and vasculitis, and predisposes to B cell lymphoma. The diagnosis of primary SS is based on a composite of clinical, serologic, and pathologic features, namely, objective evidence of dry eyes and dry mouth and either a positive test for anti-SSA (Ro) antibodies or a positive labial salivary gland biopsy. Primary SS may be confused with other conditions affecting the lacrimal and salivary glands, such as chronic hepatitis C virus infection, sarcoidosis, and a new entity, IgG4-related disease. The management of patients with primary SS is largely symptomatic and consists of tear supplementation, regular dental hygiene, and liberal use of moisturizers. Cyclosporine 0.05% ophthalmic emulsion and lifitegrast 5% ophthalmic solution are approved agents for the treatment of dry eyes. Two oral secretagogues, pilocarpine and cevimeline, have been shown in trials to significantly reduce the symptoms of dry eyes and dry mouth. Although hydroxychloroquine may reduce fatigue and joint pain, the results of a randomized controlled trial failed to confirm its efficacy in this clinical setting. More serious organ system involvement may be managed with corticosteroids and other immunomodulatory drugs. Although no disease-modifying drugs are currently approved for the treatment of primary SS, a robust pipeline of promising therapies for this disease is currently in development. This review contains 3 figures, 5 tables, and 69 references. Key words: anti-Ro/SSA antibodies, B cell lymphoma, classification criteria, EULAR Sjögren’s syndrome Patient Reported Index (ESSPRI), EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), hydroxychloroquine,  keratoconjunctivitis sicca, rituximab, Sjögren syndrome


Sign in / Sign up

Export Citation Format

Share Document